Oragenics Inc (OGEN) Stock Price, Quote & News

Company Profile

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain...

Industry: Biotechnology

Sector: Healthcare

Phone: 813 286 7900

Website: www.oragenics.com

Address:

9015 Town Center Parkway, Suite 143, Lakewood Ranch, United States

NMax Aug. 5 at 1:01 PM

$OGEN I'M STILL ADDING!! Suck it!! 🤣🤣🤣 🤑🤑🤑

0 · Reply

ExploringTrades Aug. 5 at 9:15 AM

Ticker NEXR has barely 550,000 shares outstanding. The only comparable ticker was VEEE and that one ran from 4.10$ to over 51$. NEXR released news on Aug 3rd and is shifting heavily into the AI sector. NEXR has only about 700 watchers on Stocktwits. Took a big position looking to profit massively very soon. $OGEN A>

0 · Reply

NMax Jul. 31 at 4:44 PM

$OGEN bears here are absolutely WEAK and pathetic idiots 🤣🤣🤣 Continuing to accumulate!! 🤑🤑🤑

0 · Reply

SXCross Jul. 31 at 3:58 PM

$OGEN i've bought 1000 more at 0,4899 - thanks to the shorties

1 · Reply

RocketQueen Jul. 31 at 3:17 AM

$OGEN and now the back end of the ship has reared up at a 90 degree angle to the water surface.

0 · Reply

NMax Jul. 30 at 10:21 PM

$OGEN You idiots can barely nudge the price anymore. Lol. Continuing to accumulate!! 🤑🤑🤑

0 · Reply

hyerize Jul. 30 at 7:09 PM

$OGEN how do you not buy more? I wish i had more money 💰 This will 🤯 soon. Meanwhile DFNS 😂

0 · Reply

profitingstocks Jul. 30 at 6:58 PM

$OGEN We just hit a new all time low 🎉 How are those Phase II results looking, Janet?

0 · Reply

NMax Jul. 30 at 4:21 PM

$OGEN pretty funny how badly you guys handled this one 🤣🤣🤣 Continuing to accumulate!! 🤑🤑🤑

0 · Reply

NMax Jul. 30 at 3:50 PM

$OGEN y'all bears and the oragenics management are just some idiotic cowards that got out played depsite having every tool at your disposal. Absolutely garbage people that shouldn't be allowed to even paper trade lol Continuing to accumulate!! 🤑🤑🤑

0 · Reply

Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling

May 19, 2026, 8:45 AM EDT - 2 months ago

Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21

May 18, 2026, 8:30 AM EDT - 2 months ago

ORAGENICS PROVIDES INVESTOR UPDATE

May 7, 2026, 8:30 AM EDT - 3 months ago

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

May 5, 2026, 8:30 AM EDT - 3 months ago

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

2026-04-20T14:01:13.000Z - 3 months ago

Oragenics announces 8 drug doses administered in Phase IIa trial of ONP-002

Apr 13, 2026, 8:30 AM EDT - 4 months ago

Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

2026-03-25T22:35:16.000Z - 4 months ago

Oragenics receives audit opinion with going concern explanation

Mar 25, 2026, 6:30 PM EDT - 4 months ago

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

2026-03-17T12:49:42.000Z - 5 months ago

Oragenics files annual report on Form 10-K

2026-03-12T12:48:45.000Z - 5 months ago

Oragenics initiates Phase IIa clinical trial site activation

Mar 12, 2026, 8:30 AM EDT - 5 months ago

ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION

2026-03-11T12:45:33.000Z - 5 months ago

Oragenics explores potential acquisition of additional assets in CNS space

Mar 11, 2026, 8:30 AM EDT - 5 months ago

ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION

2026-03-10T12:42:00.000Z - 5 months ago

Oragenics receives HREC approval for Phase IIa trial of ONP-002 in Australia

Mar 10, 2026, 8:30 AM EDT - 5 months ago

Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

2026-02-09T13:46:12.000Z - 6 months ago

Oragenics previews targeted milestones for 2026

Feb 9, 2026, 8:30 AM EST - 6 months ago

Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy

2026-02-03T13:40:46.000Z - 6 months ago

Oragenics partners with Duck Flats Pharma to support FDA IND trial design

Feb 3, 2026, 8:30 AM EST - 6 months ago

Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program

2026-01-22T21:15:38.000Z - 7 months ago

Oragenics files $100M mixed securities shelf

Nov 12, 2025, 8:30 AM EST - 9 months ago

Oragenics Q3 2025 Shareholder Update

2025-10-21T12:15:12.000Z - 10 months ago

Oragenics regains compliance with NYSE

Oct 21, 2025, 8:00 AM EDT - 10 months ago

Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

2025-10-07T13:20:29.000Z - 10 months ago

Oragenics, Receptor.AI partner to accelerate pipeline development

Oct 7, 2025, 8:30 AM EDT - 10 months ago

Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development

2025-08-11T12:50:19.000Z - 1 year ago

Oragenics reports Q2 EPS ($3.10) vs. ($15.27) last year.

Aug 11, 2025, 8:45 AM EDT - 1 year ago

Oragenics Q2 2025 Shareholder Update

2025-07-31T12:52:03.000Z - 1 year ago

Oragenics selects South Star Research as its CRO for ONP-002 Phase IIa trial

2025-07-16T12:45:56.000Z - 1 year ago

Oragenics announces manufacturing agreement with Sterling Pharma for ONP-002

Jul 16, 2025, 8:39 AM EDT - 1 year ago

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

Jul 2, 2025, 4:15 PM EDT - 1 year ago

Oragenics Completes Approximately $16.5 Million Offering

2025-07-02T01:00:00.000Z - 1 year ago

Why Is Oragenics Stock (OGEN) Down 55% Today?

2025-07-01T12:50:11.000Z - 1 year ago

Oragenics trading resumes

2025-07-01T12:41:48.000Z - 1 year ago

Oragenics prices 800,000 shares of Preferred Stock at $25.00 in public offering

Jul 1, 2025, 8:31 AM EDT - 1 year ago

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

2025-07-01T12:05:53.000Z - 1 year ago

Oragenics trading halted, news pending

2025-06-03T13:40:31.000Z - 1 year ago

Oragenics trading resumes

May 13, 2025, 8:30 AM EDT - 1 year ago

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

May 12, 2025, 8:30 AM EDT - 1 year ago

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

Apr 7, 2025, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Mar 27, 2025, 8:30 AM EDT - 1 year ago

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Mar 18, 2025, 5:33 PM EDT - 1 year ago

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Mar 6, 2025, 9:30 AM EST - 1 year ago

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Feb 25, 2025, 8:30 AM EST - 1 year ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Feb 11, 2025, 8:30 AM EST - 1 year ago

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Feb 5, 2025, 8:15 AM EST - 1 year ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Jan 21, 2025, 8:15 AM EST - 1 year ago

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Dec 16, 2024, 8:09 AM EST - 1 year ago

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Oct 18, 2024, 8:30 AM EDT - 1 year ago

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oct 8, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Sep 5, 2024, 4:30 PM EDT - 2 years ago

Oragenics, Inc. Announces Closing of Public Offering

Sep 4, 2024, 8:36 AM EDT - 2 years ago

Oragenics, Inc. Announces Pricing of Public Offering

Aug 21, 2024, 8:45 AM EDT - 2 years ago

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Aug 16, 2024, 4:30 PM EDT - 2 years ago

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Aug 14, 2024, 8:30 AM EDT - 2 years ago

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Aug 12, 2024, 8:30 AM EDT - 2 years ago

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Aug 8, 2024, 8:45 AM EDT - 2 years ago

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Jun 27, 2024, 8:30 AM EDT - 2 years ago

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Jun 24, 2024, 6:43 PM EDT - 2 years ago

Oragenics, Inc. Announces Proposed Public Offering

May 22, 2024, 8:00 AM EDT - 2 years ago

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

May 17, 2024, 8:00 AM EDT - 2 years ago

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

Apr 19, 2024, 5:50 PM EDT - 2 years ago

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Apr 1, 2024, 9:05 AM EDT - 2 years ago

Oragenics, Inc. Files 10K and Provides Company Update

Mar 18, 2024, 7:00 AM EDT - 2 years ago

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Mar 5, 2024, 7:45 AM EST - 2 years ago

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Mar 1, 2024, 4:04 PM EST - 2 years ago

Oragenics Announces Closing of Public Offering

Feb 27, 2024, 9:25 PM EST - 2 years ago

Oragenics Announces Pricing of Public Offering

NMax Aug. 5 at 1:01 PM

$OGEN I'M STILL ADDING!! Suck it!! 🤣🤣🤣 🤑🤑🤑

0 · Reply

ExploringTrades Aug. 5 at 9:15 AM

0 · Reply

NMax Jul. 31 at 4:44 PM

$OGEN bears here are absolutely WEAK and pathetic idiots 🤣🤣🤣 Continuing to accumulate!! 🤑🤑🤑

0 · Reply

SXCross Jul. 31 at 3:58 PM

$OGEN i've bought 1000 more at 0,4899 - thanks to the shorties

1 · Reply

RocketQueen Jul. 31 at 3:17 AM

$OGEN and now the back end of the ship has reared up at a 90 degree angle to the water surface.

0 · Reply

NMax Jul. 30 at 10:21 PM

$OGEN You idiots can barely nudge the price anymore. Lol. Continuing to accumulate!! 🤑🤑🤑

0 · Reply

hyerize Jul. 30 at 7:09 PM

$OGEN how do you not buy more? I wish i had more money 💰 This will 🤯 soon. Meanwhile DFNS 😂

0 · Reply

profitingstocks Jul. 30 at 6:58 PM

$OGEN We just hit a new all time low 🎉 How are those Phase II results looking, Janet?

0 · Reply

NMax Jul. 30 at 4:21 PM

$OGEN pretty funny how badly you guys handled this one 🤣🤣🤣 Continuing to accumulate!! 🤑🤑🤑

0 · Reply

NMax Jul. 30 at 3:50 PM

0 · Reply

NMax Jul. 29 at 4:38 PM

$OGEN A bunch of cowards trying to run this lmao 🤣 Anyways...continuing to accumulate!! 🤑🤑🤑

0 · Reply

NMax Jul. 29 at 3:57 PM

$OGEN Hey moron bears, lets see that discount. Chop chop! 🤑🤑🤑

0 · Reply

NMax Jul. 28 at 8:57 PM

$OGEN who do these bears think is listening to them lol! I'm going to keep adding. In fact I would love to double my holdings if you idiots would generously lower it just a little bit. 😁 🤑🤑🤑

0 · Reply

profitingstocks Jul. 28 at 8:38 PM

$OGEN 1/5th of a cent off all time low, yeah exactly what you’d expect from a company that’s supposedly about to enter an untapped multibillion dollar market

0 · Reply

NMax Jul. 28 at 7:02 PM

$OGEN I think I'll add another 50,000 shares Monday. 🙂 Why not. This price is a dream come true!! 🤑🤑🤑

0 · Reply

SXCross Jul. 28 at 5:45 PM

$OGEN short interest 783.091 shares !!

1 · Reply

Makethatmoneyson Jul. 28 at 5:19 PM

$OGEN when is liftoff 🚀🚀🚀

1 · Reply

NMax Jul. 27 at 7:24 PM

$OGEN I'm about to add...a LOT more. 😘 🤑🤑🤑

0 · Reply

sincosine Jul. 27 at 4:04 PM

$OGEN total shit stock and a scam. Management is definitely pocketing your money . I am sure some of you are working with these scammers. Promoting this MF shit 💩!

1 · Reply

NMax Jul. 21 at 9:59 PM

$OGEN so anyways... Continuing to accumulate!! 🤑🤑🤑

0 · Reply

profitingstocks Jul. 21 at 4:35 PM

$OGEN seems to be getting 1 cent lower per day, if it continues we’ll have a brand new all time low by the end of the week. I say Janet deserves another $200,000 performance bonus

0 · Reply

NMax Jul. 18 at 11:55 PM

$OGEN So... Why does it even matter to racketpeon what I do with my own money lol Why do they care whether I add or how many shares I have lol Why is racketpeon spending this much time and effort on someone that blocked racketpeon years ago... Continuing to accumulate!! 🤑🤑🤑

0 · Reply

Market Cap	2.44M
Revenue (ttm)	0.00
Net Income (ttm)	-9.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	5,841
Avg Vol	38,028
Day's Range	N/A - N/A
Shares Out	4.51M
Stochastic %K	79%
Beta	1.24
Analysts	Strong Buy
Price Target	$2.00